What is Salarius Pharmaceuticals Inc's earnings per share (EPS)?

Salarius Pharmaceuticals Inc (SLRX) reported diluted earnings per share of $-129.10 for fiscal year 2025. EPS represents the portion of a company's net income allocated to each outstanding share of common stock and is widely used to evaluate profitability on a per-share basis.

Salarius Pharmaceuticals Inc Financials

SLRX

Source SEC Filings (10-K/10-Q) Updated Mar 31, 2026 Currency USD FYE December

This page shows Salarius Pharmaceuticals Inc (SLRX) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 11 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).

Rhea AI SLRX FY2025 2026-04-22

Equity financing is sustaining a shrinking research program, leaving Salarius cash-restocked but not self-funded by operations.

FY2025 cash climbed to $10.7M from $2.4M even though free cash flow stayed negative, so the stronger cash balance did not come from operations. Financing inflow of $12.3M exceeded free cash outflow of -$5.4M, showing liquidity was rebuilt externally rather than earned.

Research spending fell from $15.8M in FY2022 to $368K in FY2025. SG&A only declined from $7.1M to $3.7M, so the remaining cost base is now more administrative than research-driven, which usually means the organization is preserving corporate continuity rather than expanding development work.

The FY2025 net loss of -$12.5M was far larger than operating cash outflow of -$4.8M, so accounting losses and cash consumption are not moving one-for-one. Cash still exceeded total liabilities at $10.7M versus $5.2M, making near-term solvency more dependent on continued capital access than on debt repayment pressure.

Financial Health Signals

Financial Profile 20/100

Based on FY2025 annual data, averaged across the last 3 years for performance metrics (most-recent year weighted highest). How this score is calculated →

Health score ≠ stock price. This rates the quality of Salarius Pharmaceuticals Inc's business: profitability, growth, balance sheet strength. It doesn't tell you whether the stock is a good buy at today's price. Not financial advice. Use it alongside valuation analysis and your own research.

Leverage

Salarius Pharmaceuticals Inc carries a low D/E ratio of 0.88, meaning only $0.88 of long-term debt for every $1 of shareholders' equity. This conservative leverage earns a score of 84/100, indicating a strong balance sheet with room for future borrowing.

Liquidity

Salarius Pharmaceuticals Inc's current ratio of 2.13 indicates adequate short-term liquidity, earning a score of 39/100. The company can meet its near-term obligations, though with limited headroom.

Returns

Salarius Pharmaceuticals Inc generates a -212.6% ROE, indicating limited profit relative to shareholders' investment. This results in a returns score of 0/100. This is up from -368.8% the prior year.

Piotroski F-Score Neutral

4/9

Salarius Pharmaceuticals Inc passes 4 of 9 financial strength tests. 2 of 4 profitability signals pass, 2 of 3 leverage/liquidity signals pass.

Earnings Quality Low Quality

0.39x

For every $1 of reported earnings, Salarius Pharmaceuticals Inc generates $0.39 in operating cash flow (-$4.8M OCF vs -$12.5M net income). This low ratio suggests earnings are primarily driven by accounting accruals rather than cash generation, which may not be sustainable.

Key Financial Metrics

Export CSV

Earnings & Revenue

Revenue

N/A

EBITDA

-$12.6M

YoY-120.0%

Salarius Pharmaceuticals Inc's EBITDA was -$12.6M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization. This represents a decrease of 120.0% from the prior year.

Net Income

-$12.5M

YoY-124.5%

Salarius Pharmaceuticals Inc reported -$12.5M in net income in fiscal year 2025. This represents a decrease of 124.5% from the prior year.

EPS (Diluted)

$-129.10

Salarius Pharmaceuticals Inc earned $-129.10 per diluted share (EPS) in fiscal year 2025. This represents a decrease of 85.6% from the prior year.

Cash & Balance Sheet

Free Cash Flow

-$5.4M

YoY-19.4%

Salarius Pharmaceuticals Inc generated -$5.4M in free cash flow in fiscal year 2025, representing cash available after capex. This represents a decrease of 19.4% from the prior year.

Cash & Debt

$10.7M

YoY+339.9%

5Y CAGR-0.7%

10Y CAGR-16.7%

Salarius Pharmaceuticals Inc held $10.7M in cash against $0 in long-term debt as of fiscal year 2025.

Dividends Per Share

N/A

Shares Outstanding

8,006

Salarius Pharmaceuticals Inc had 8,006 shares outstanding in fiscal year 2025. This represents a decrease of 91.7% from the prior year.

Margins & Returns

Gross Margin

N/A

Operating Margin

N/A

Net Margin

N/A

Return on Equity

-212.6%

YoY+156.3pp

5Y CAGR-179.4pp

10Y CAGR-181.0pp

Salarius Pharmaceuticals Inc's ROE was -212.6% in fiscal year 2025, measuring profit generated per dollar of shareholder equity. This is up 156.3 percentage points from the prior year.

Capital Allocation

R&D Spending

$368K

YoY-52.2%

5Y CAGR-44.4%

10Y CAGR-29.8%

Salarius Pharmaceuticals Inc invested $368K in research and development in fiscal year 2025. This represents a decrease of 52.2% from the prior year.

Share Buybacks

N/A

Capital Expenditures

$577K

5Y CAGR+194.6%

10Y CAGR+8.1%

Salarius Pharmaceuticals Inc invested $577K in capex in fiscal year 2025, funding long-term assets and infrastructure.

SLRX Income Statement

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Revenue	N/A	N/A	N/A	$0-100.0%	$1.8M-64.8%	$5.2M
Cost of Revenue	N/A	N/A	N/A	N/A	N/A	N/A
Gross Profit	N/A	N/A	N/A	N/A	N/A	N/A
R&D Expenses	$368K-52.2%	$770K-89.3%	$7.2M-54.7%	$15.8M+85.3%	$8.5M+23.6%	$6.9M
SG&A Expenses	$3.7M-24.9%	$5.0M-13.2%	$5.7M-19.9%	$7.1M+16.9%	$6.1M0.0%	$6.1M
Operating Income	-$12.6M-120.0%	-$5.7M+55.5%	-$12.9M+59.5%	-$31.8M-148.5%	-$12.8M-64.6%	-$7.8M
Interest Expense	N/A	N/A	N/A	N/A	N/A	N/A
Income Tax	$0	N/A	N/A	N/A	N/A	N/A
Net Income	-$12.5M-124.5%	-$5.6M+55.5%	-$12.5M+60.3%	-$31.6M-147.6%	-$12.8M-73.7%	-$7.4M
EPS (Diluted)	$-129.10	$-69.54	$-30.74	$-14.88-92.7%	$-7.72	$-0.50

Metric	Q1'26	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24	Q2'24
Revenue	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Cost of Revenue	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Gross Profit	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
R&D Expenses	$750K	N/A	$62K-46.9%	$116K+54.1%	$76K	N/A	$137K-36.0%	$214K
SG&A Expenses	$1.5M	N/A	$833K-1.9%	$849K-48.3%	$1.6M	N/A	$869K-30.6%	$1.3M
Operating Income	-$2.3M	N/A	-$895K+7.3%	-$966K+43.8%	-$1.7M	N/A	-$1.0M+31.4%	-$1.5M
Interest Expense	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Income Tax	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Net Income	-$2.2M	N/A	-$873K+8.8%	-$958K+44.0%	-$1.7M	N/A	-$972K+31.8%	-$1.4M
EPS (Diluted)	$-4.18	N/A	$-1.81-302.2%	$-0.45	$-240.07	N/A	$-11.38-380.2%	$-2.37

SLRX Balance Sheet

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Total Assets	$11.1M+265.8%	$3.0M-54.1%	$6.6M-55.0%	$14.7M-64.1%	$40.8M+63.8%	$24.9M
Current Assets	$11.0M+267.7%	$3.0M-54.2%	$6.5M-55.1%	$14.5M-51.9%	$30.2M+90.9%	$15.8M
Cash & Equivalents	$10.7M+339.9%	$2.4M-58.7%	$5.9M-51.3%	$12.1M-58.6%	$29.2M+162.8%	$11.1M
Inventory	N/A	N/A	N/A	N/A	N/A	N/A
Accounts Receivable	N/A	N/A	N/A	N/A	N/A	N/A
Goodwill	N/A	N/A	N/A	$0-100.0%	$8.9M0.0%	$8.9M
Total Liabilities	$5.2M+241.9%	$1.5M+16.3%	$1.3M-69.5%	$4.3M+102.1%	$2.1M-23.9%	$2.8M
Current Liabilities	$5.2M+241.9%	$1.5M	N/A	N/A	N/A	N/A
Long-Term Debt	N/A	N/A	N/A	N/A	N/A	N/A
Total Equity	$5.9M+289.6%	$1.5M-71.4%	$5.3M-49.1%	$10.4M-73.2%	$38.7M+74.7%	$22.2M
Retained Earnings	-$94.4M-15.3%	-$81.9M-7.3%	-$76.3M-19.7%	-$63.8M-98.2%	-$32.2M-65.7%	-$19.4M

Metric	Q1'26	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24	Q2'24
Total Assets	$8.4M-23.8%	$11.1M+81.3%	$6.1M+337.8%	$1.4M-40.5%	$2.3M-22.6%	$3.0M-21.7%	$3.9M+8.6%	$3.6M
Current Assets	$8.4M-23.9%	$11.0M+81.1%	$6.1M+346.1%	$1.4M-41.0%	$2.3M-22.8%	$3.0M-21.8%	$3.8M+8.8%	$3.5M
Cash & Equivalents	$7.8M-27.0%	$10.7M+122.7%	$4.8M+505.1%	$795K-55.8%	$1.8M-26.1%	$2.4M-25.9%	$3.3M+0.3%	$3.3M
Inventory	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Accounts Receivable	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Goodwill	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Total Liabilities	$4.5M-12.0%	$5.2M+179.5%	$1.8M-16.8%	$2.2M-2.4%	$2.3M+50.7%	$1.5M+61.7%	$935K-20.7%	$1.2M
Current Liabilities	$4.5M-12.0%	$5.2M	N/A	N/A	N/A	$1.5M	N/A	N/A
Long-Term Debt	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Total Equity	$3.9M-34.2%	$5.9M+38.6%	$4.2M+612.0%	-$830K-1441.2%	$62K-95.9%	$1.5M-48.3%	$2.9M+23.1%	$2.4M
Retained Earnings	-$96.7M-2.4%	-$94.4M-10.5%	-$85.5M-1.0%	-$84.6M-1.1%	-$83.6M-2.1%	-$81.9M-1.8%	-$80.5M-1.2%	-$79.5M

SLRX Cash Flow Statement

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Operating Cash Flow	-$4.8M-6.7%	-$4.5M+64.8%	-$12.8M+27.0%	-$17.6M-72.5%	-$10.2M+1.1%	-$10.3M
Capital Expenditures	$577K	$0	N/A	N/A	$0-100.0%	$3K
Free Cash Flow	-$5.4M-19.4%	-$4.5M	N/A	N/A	-$10.2M+1.1%	-$10.3M
Investing Cash Flow	$765K	$0	$0+100.0%	-$1.5M	$0+100.0%	-$3K
Financing Cash Flow	$12.3M+1064.0%	$1.1M-84.0%	$6.6M+234.1%	$2.0M-93.0%	$28.3M+59.9%	$17.7M
Dividends Paid	N/A	N/A	N/A	N/A	N/A	$0
Share Buybacks	N/A	N/A	N/A	N/A	N/A	N/A

Metric	Q1'26	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24	Q2'24
Operating Cash Flow	-$2.9M-154.2%	-$1.1M+31.0%	-$1.6M-91.0%	-$862K+27.0%	-$1.2M-59.1%	-$743K+45.3%	-$1.4M-26.5%	-$1.1M
Capital Expenditures	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Free Cash Flow	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Investing Cash Flow	N/A	$965K	N/A	N/A	N/A	$0	N/A	N/A
Financing Cash Flow	$0-100.0%	$6.1M+3.6%	$5.9M+4251.3%	-$141K-125.9%	$546K+610.0%	-$107K-107.8%	$1.4M+4952.4%	-$28K
Dividends Paid	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Share Buybacks	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

SLRX Financial Ratios

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Gross Margin	N/A	N/A	N/A	N/A	N/A	N/A
Operating Margin	N/A	N/A	N/A	N/A	-696.3%-547.5pp	-148.8%
Net Margin	N/A	N/A	N/A	N/A	-693.8%-553.4pp	-140.5%
Return on Equity	-212.6%+156.3pp	-368.8%-131.6pp	-237.2%+67.2pp	-304.4%-271.4pp	-33.0%+0.2pp	-33.2%
Return on Assets	-113.2%+71.2pp	-184.4%+6.0pp	-190.4%+25.3pp	-215.7%-184.5pp	-31.3%-1.8pp	-29.5%
Current Ratio	2.13+0.1	1.98	N/A	N/A	N/A	N/A
Debt-to-Equity	0.88-0.1	1.00+0.8	0.25-0.2	0.41+0.4	0.05-0.1	0.13
FCF Margin	N/A	N/A	N/A	N/A	-554.3%-357.2pp	-197.1%

Metric	Q1'26	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24	Q2'24
Gross Margin	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Operating Margin	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Net Margin	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Return on Equity	-57.4%	N/A	-20.6%	N/A	-2763.3%	N/A	-33.2%+26.7pp	-60.0%
Return on Assets	-26.4%	N/A	-14.3%+54.4pp	-68.8%+4.3pp	-73.1%	N/A	-25.2%+14.9pp	-40.1%
Current Ratio	1.84-0.3	2.13	N/A	N/A	N/A	1.98	N/A	N/A
Debt-to-Equity	1.17+0.3	0.88+0.4	0.44+3.1	-2.68-39.5	36.81+35.8	1.00+0.7	0.32-0.2	0.50
FCF Margin	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Similar Companies

Gt Biopharma Inc GTBP

$15.9M

Protagenic Therapeutics Inc PTIX

$1.4M

Lipella Pharmaceuticals Inc LIPO

$11.8M

Indaptus Therapeutics Inc INDP

$138.2M

Scinai Immunotherapeutics Ltd. SCNI

$1.8M

Frequently Asked Questions

Is Salarius Pharmaceuticals Inc profitable?

No, Salarius Pharmaceuticals Inc (SLRX) reported a net income of -$12.5M in fiscal year 2025.

What is Salarius Pharmaceuticals Inc's EBITDA?

Salarius Pharmaceuticals Inc (SLRX) had EBITDA of -$12.6M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.

What is Salarius Pharmaceuticals Inc's return on equity (ROE)?

Salarius Pharmaceuticals Inc (SLRX) has a return on equity of -212.6% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.

What is Salarius Pharmaceuticals Inc's free cash flow?

Salarius Pharmaceuticals Inc (SLRX) generated -$5.4M in free cash flow during fiscal year 2025. This represents a -19.4% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.

What is Salarius Pharmaceuticals Inc's operating cash flow?

Salarius Pharmaceuticals Inc (SLRX) generated -$4.8M in operating cash flow during fiscal year 2025, representing cash generated from core business activities.

What are Salarius Pharmaceuticals Inc's total assets?

Salarius Pharmaceuticals Inc (SLRX) had $11.1M in total assets as of fiscal year 2025, including both current and long-term assets.

What are Salarius Pharmaceuticals Inc's capital expenditures?

Salarius Pharmaceuticals Inc (SLRX) invested $577K in capital expenditures during fiscal year 2025, funding long-term assets and infrastructure.

How much does Salarius Pharmaceuticals Inc spend on research and development?

Salarius Pharmaceuticals Inc (SLRX) invested $368K in research and development during fiscal year 2025.

How many shares does Salarius Pharmaceuticals Inc have outstanding?

Salarius Pharmaceuticals Inc (SLRX) had 8,006 shares outstanding as of fiscal year 2025.

What is Salarius Pharmaceuticals Inc's current ratio?

Salarius Pharmaceuticals Inc (SLRX) had a current ratio of 2.13 as of fiscal year 2025, which is generally considered healthy.

What is Salarius Pharmaceuticals Inc's debt-to-equity ratio?

Salarius Pharmaceuticals Inc (SLRX) had a debt-to-equity ratio of 0.88 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.

What is Salarius Pharmaceuticals Inc's return on assets (ROA)?

Salarius Pharmaceuticals Inc (SLRX) had a return on assets of -113.2% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.

What is Salarius Pharmaceuticals Inc's cash runway?

Based on fiscal year 2025 data, Salarius Pharmaceuticals Inc (SLRX) had $10.7M in cash against an annual operating cash burn of $4.8M. This gives an estimated cash runway of approximately 27 months at the current burn rate. Cash runway measures how long a company can continue operating before running out of cash, assuming no additional funding.

What is Salarius Pharmaceuticals Inc's Piotroski F-Score?

Salarius Pharmaceuticals Inc (SLRX) has a Piotroski F-Score of 4 out of 9, indicating neutral financial health. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.

Are Salarius Pharmaceuticals Inc's earnings high quality?

Salarius Pharmaceuticals Inc (SLRX) has an earnings quality ratio of 0.39x, considered low quality (accrual-driven). This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.

How financially healthy is Salarius Pharmaceuticals Inc?

Salarius Pharmaceuticals Inc (SLRX) scores 20 out of 100 on our Financial Profile, indicating weak overall financial health. This composite score evaluates six dimensions: profitability (operating margin), revenue growth, leverage (debt-to-equity), liquidity (current ratio), cash flow quality (free cash flow margin), and shareholder returns (return on equity). Each dimension is normalized against standard financial benchmarks. Learn more in our complete guide to financial health indicators.